The bill
MAPS Act
S. 1784, 119th Congress — read as touching Biotech & Research.
MAPS Act
Download PDFBill ID: 119/s/1784
Last Updated: September 2, 2026
Sponsored by
Sen. Peters, Gary C. [D-MI]
ID: P000595
Follow the money
The sponsor
Sen. Peters, Gary C. [D-MI]
Every bill has someone who introduced it. That name is where the paper trail starts.
The money
$76,900 raised
30 itemised contributions to this sponsor, pulled from FEC filings.
The alignment
85% match to Project 2025
This bill's text tracks the "Department of Health and Human Services" section, p. 488-490 of the Mandate for Leadership.
Bill's Journey to Becoming a Law
Track this bill's progress through the legislative process
Latest Action
Committee on Health, Education, Labor, and Pensions. Hearings held.
March 18, 2026
Introduced
Committee Review
📍 Current Status
Next: The bill moves to the floor for full chamber debate and voting.
🗳️
Floor Action
✅
Passed Senate
🏛️
House Review
🎉
Passed Congress
🖊️
Presidential Action
⚖️
Became Law
📚 How does a bill become a law?
1. Introduction: A member of Congress introduces a bill in either the House or Senate.
2. Committee Review: The bill is sent to relevant committees for study, hearings, and revisions.
3. Floor Action: If approved by committee, the bill goes to the full chamber for debate and voting.
4. Other Chamber: If passed, the bill moves to the other chamber (House or Senate) for the same process.
5. Conference: If both chambers pass different versions, a conference committee reconciles the differences.
6. Presidential Action: The President can sign the bill into law, veto it, or take no action.
7. Became Law: If signed (or if Congress overrides a veto), the bill becomes law!
Bill Summary
Another brilliant example of congressional theater, masquerading as a genuine attempt to address the nation's pharmaceutical supply chain vulnerabilities. The MAPS Act is a masterclass in bureaucratic doublespeak, designed to create the illusion of action while actually accomplishing very little.
**Main Purpose & Objectives:** The bill's stated purpose is to improve coordination among federal agencies to identify and mitigate health and national security risks associated with essential medicines. In reality, it's a thinly veiled attempt to justify increased government control over the pharmaceutical industry, under the guise of "national security" concerns.
**Key Provisions & Changes to Existing Law:** The bill creates an "Essential Medicines List," which will be updated every two years, and requires the Secretary of Health and Human Services to conduct a comprehensive risk assessment of the supply chains for these essential medicines. It also establishes a monitoring system to map pharmaceutical supply chains using data analytics.
**Affected Parties & Stakeholders:** The usual suspects are involved in this farce: pharmaceutical companies, federal agencies, and congressional committees. The bill's sponsors, including Senators Peters, Lankford, Ernst, Cotton, Kaine, King, and Scott of Florida, are either naive or complicit in this charade.
**Potential Impact & Implications:** The MAPS Act will likely lead to increased regulatory burdens on pharmaceutical companies, driving up costs and potentially reducing innovation. The bill's focus on "national security" risks is a red herring, as the real concern is the government's desire to exert greater control over the industry. This legislation may also create new opportunities for crony capitalism, as favored companies receive preferential treatment in the form of government contracts or subsidies.
In conclusion, the MAPS Act is a classic example of legislative malpractice. It's a symptom of a deeper disease: the insatiable appetite of politicians to expand their power and control over the economy, while pretending to serve the public interest. As with any terminal illness, the prognosis is grim – more bureaucratic bloat, increased costs, and reduced innovation in the pharmaceutical industry.
Diagnosis: Congressional Theater Syndrome (CTS), characterized by grandstanding, obfuscation, and a complete disregard for the consequences of one's actions. Treatment: None available; the patient is terminal.
Related Topics
Healthcare & Insurance ReformPublic Health & Pandemic Response
Generated using Llama 3.1 70B (Dr. Haus personality)
💰 Campaign Finance Network
Sen. Peters, Gary C. [D-MI]
Congress 119 • 2024 Election Cycle
Total Contributions
$983,428
604 donors
PACs
$0
Organizations
$43,800
Committees
$0
Individuals
$939,628
No PAC contributions found
1
OTOE MISSOURIA TRIBE OF OKLAHOMA
$7,900
2
TURTLE MOUNTAIN BAND OF CHIPPEWA TRIBE OF NORTH DAKOTA
$7,900
3
HABEMATOLEL POMO OF UPPER LAKE TRIBE OF CALIFORNIA
$5,400
4
MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS
$5,000
5
MUCKLESHOOT INDIAN TRIBE
$4,300
6
STRATEGIC LINK CONSULTING, LP
$3,300
7
CHEROKEE NATION
$2,500
8
NOTTAWASEPI HURON BAND OF THE POTAWATOMI
$2,000
9
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
$2,000
10
TRANSPOND, LLC
$2,000
11
SUQUAMISH INDIAN TRIBE
$1,000
12
KW BRADLEY ASSOCIATES
$500
No committee contributions found
1
ARNOLD, LAURA
$6,600
2
ATTWOOD, JAMES ALBERT JR
$6,600
3
BOURLA, ALBERT
$6,600
4
HALE, KAREN
$6,600
5
KALISMAN, HILARY
$6,600
6
KALISMAN, JASON TAUBMAN
$6,600
7
KALISMAN, PHILIP
$6,600
8
O'DAY, DANIEL
$6,600
9
ROSE, JONATHAN
$6,600
10
SIMMONS, IAN
$6,600
11
WU, ALBERT
$6,600
12
CAREY, SUSANNA
$5,900
13
ISRAEL, HOWARD
$5,900
14
NICKERSON, MARTINUS H.
$5,600
15
NESSEL, ARIEL
$5,500
16
EMERSON, LANGSTON C.
$5,400
17
HART, MICHAEL
$5,400
18
HOWARD, BARRY L.
$5,000
19
SEIKALY, WILLIAM R.
$5,000
20
SIMMONS, JOHN
$5,000
21
SKERBECK, SONJA
$5,000
22
STRASBERG, ROBERT
$5,000
23
NIEMIEC, AUSTIN
$4,700
24
DESAI, ANKIT
$4,500
25
NELSON, JAMES
$4,200
26
GRIX, HENRY M.
$4,100
27
HOWELL, ANDREW
$4,100
28
STAPLETON, THOMAS
$4,000
29
RICCHETTI, JEFF
$3,800
30
ABRAMS, NINA DODGE
$3,700
31
ANDREESSEN, MARC
$3,300
32
BANFIELD, WILLIAM
$3,300
33
BARROSSE, DAVID
$3,300
34
BOERNER, CHRISTOPHER
$3,300
35
BRADWAY, ROBERT
$3,300
36
BRIDGES, ELAINE
$3,300
37
CARROLL, COLIN
$3,300
38
CHU, MORGAN
$3,300
39
DAVIS, ROBERT M.
$3,300
40
DIXON, CHRIS
$3,300
41
EMERSON, BILL
$3,300
42
GIBBS, SAMUEL
$3,300
43
HALL JR., DON
$3,300
44
HARDY, ALEXANDER
$3,300
45
HAUSMANN, ESTHER
$3,300
46
HOBERMAN, TOM
$3,300
47
HOROWITZ, BEN
$3,300
48
JUNCOSA, MARK
$3,300
49
KRAMER, ANDREA
$3,300
50
LEPRINO, TERRY L.
$3,300
51
LIPSKAR, SIMON
$3,300
52
MIRMEHDI, MICHEAL
$3,300
53
NYMAN, MELISSA
$3,300
54
NYMAN, SPENCER
$3,300
55
PHELAN, DANIEL J.
$3,300
56
RICKS, DAVID
$3,300
57
SEABOLT, DOUG
$3,300
58
SHOTWELL, GWYNNE
$3,300
59
SMITH, JIM
$3,300
60
TAND, MOHAMMAD R.
$3,300
61
TELLIER, J. CHRISTOPHE
$3,300
62
WHEAT, ALAN D.
$3,300
63
WILLIAMS, LESLIE K.
$3,300
64
YOUNGMAN, ANDREW
$3,300
65
SMITH, PAMELA
$3,200
66
BELL, JAMES EDWARD III
$3,100
67
MISCIKOWSKI, CYNTHIA
$3,100
68
DWYER, DENIS II
$3,000
69
GOODE, CHRISTOPHER J
$3,000
70
GREENE, BARRY E.
$3,000
71
HIGGINBOTTOM, ELZIE L.
$3,000
72
HOBERMAN, ELLEN
$3,000
73
KIME, CARL
$3,000
74
KOHN, GERALD
$3,000
75
LYONS, TOM
$3,000
76
MCLAUGHLIN, BRIAN
$3,000
77
PARVEN, SCOTT
$3,000
78
STANTON, MARY BETH
$3,000
79
WIGGINS, CHANI
$3,000
80
SCHLEIN, TED
$2,900
81
TISCH, JONATHAN M.
$2,900
82
TISCH, LIZZIE
$2,900
83
BICKWIT, LEONARD JR
$2,800
84
KAPLAN, JAMES
$2,800
85
LABULA, JOSEPH
$2,750
86
DUFFORD, WILLIAM E.
$2,700
87
HERRMANN, MATTHEW
$2,700
88
KOONCE, TOM
$2,700
89
FETTIG, DWIGHT
$2,600
90
KLEIN, ISRAEL
$2,600
91
MYERS, CAROL
$2,600
92
ALSUP, WILLIAM BYRN III
$2,500
93
BLOOM, ELAINE
$2,500
94
BRITTON, JOSEPH
$2,500
95
BYERS, DAVID
$2,500
96
EBRAHIMI, MEHRAN
$2,500
97
FRYMOYER, BILL
$2,500
98
GARSON, BRETT
$2,500
99
GRESHAM, DANA
$2,500
100
HARRIS, JOI
$2,500
101
JONES, BOB
$2,500
102
JUDKINS, JAMES
$2,500
103
MCBRIDE, LINCOLN
$2,500
104
MILLER, ROBERT
$2,500
105
NORCIA, JERRY
$2,500
106
SMITH, MICHAEL
$2,500
107
VEALENCIS, JOSEPH J.
$2,500
108
VIEHBACHER, CHRISTOPHER
$2,500
109
WHITTEN, LORI
$2,500
110
ZIARKO, JEFF
$2,500
111
NELSON, MARY G.
$2,300
112
CAREY, STEPHEN
$2,200
113
FORBES, JEFFREY
$2,200
114
GURLEY, JOHN
$2,200
115
MOTTUR, AL E.
$2,200
116
DEWITT, CHARLIE
$2,100
117
KESHISHIAN, MARC D.
$2,100
118
POMPER, BRIAN
$2,100
119
SIMON, DEBORAH
$2,100
120
BELL, DAWN
$2,000
121
BOYLE, DAPHNE
$2,000
122
BRAMWELL, ADAM
$2,000
123
BUNDSCHUH, RUSSELL
$2,000
124
CURRIE, MARY C.
$2,000
125
DILLON, BRANDON
$2,000
126
FERGUSON, KATHLEEN
$2,000
127
GILL, DEREK
$2,000
128
HALL, JEAN
$2,000
129
HARRIS, SHELDON
$2,000
130
IRBY, WILLIAM
$2,000
131
KEMLER, JAMES
$2,000
132
KHODADOST, FATOLLAH
$2,000
133
KNOX, KENNETH
$2,000
134
KRATZ, SUSAN K.
$2,000
135
LASALA, BARRY
$2,000
136
MEEHAN, LAWRENCE
$2,000
137
MINGOLELLI, MICHAEL
$2,000
138
NAGHIPOUR, HAMIDREZA
$2,000
139
NAISON-PHILLIPS, ERIC
$2,000
140
NEMOVI, MOSTAFA
$2,000
141
PAPPAS, NORMAN A.
$2,000
142
PERRICH, DOROTHY M.
$2,000
143
POLESE, DONALD
$2,000
144
ROBINSON, ELLEN K.
$2,000
145
RUSH, ANDRA M.
$2,000
146
SLAY, BRENT L.
$2,000
147
SPECK, ADAM
$2,000
148
SPICER, TRACY B.
$2,000
149
TOUGH, CAROL L.
$2,000
150
TRIGGER, GRANT R.
$2,000
151
TURLEY, JERI
$2,000
152
WAUN, THOMAS W.
$2,000
153
WEINSTEIN, ANNA
$2,000
154
WORTH, PETER
$2,000
155
MICALI, MARK
$1,900
156
LEA, JASON
$1,800
157
TAYLOR, GORDON
$1,800
158
ARRILLAGA-ANDREESSEN, LAURA
$1,700
159
GUIDA, ALFONSO JR.
$1,700
160
HERMANOFF, SANDY M.
$1,700
161
HOROWITZ, FELICIA
$1,700
162
OBERSCHMIDT, DAVID W.
$1,700
163
PETERSON, CARL
$1,700
164
RAYMOND, LAWRENCE B.
$1,700
165
SILENOK, ELENA
$1,700
166
KAROUB, ALICE M.
$1,670
167
LEWIS, BILL R.
$1,655
168
CHEWNING, KIRK
$1,650
169
JOHNSON, DAVID
$1,650
170
ADAMS, RANDY
$1,500
171
ARYA, MANOOCHER
$1,500
172
ASSARIAN, GARY
$1,500
173
ATESIAN, HOWARD P.
$1,500
174
BALDEVIA, LORRIE
$1,500
175
BERMAN, ELLEN
$1,500
176
BERNSTEIN, MATTHEW
$1,500
177
BLOWER, SUSAN
$1,500
178
CHARLES, STEPHEN
$1,500
179
CHENEY, BRADFORD
$1,500
180
DE BOOR, CARL RAE
$1,500
181
EDEN, BRENT
$1,500
182
FAZILI, SAMIRA
$1,500
183
FOLEY, FRED
$1,500
184
JAMIAN, JOHN
$1,500
185
KESSINGER, JOHN
$1,500
186
KIM, JULIE
$1,500
187
KREIKEMEIER, CHAD
$1,500
188
KROVI, VENKATASATYA
$1,500
189
KURIAN, THOMAS
$1,500
190
LUNDE, JOHN
$1,500
191
MASON, MARCUS
$1,500
192
MCKENNA, REGIS
$1,500
193
MERRIGAN, JOHN A.
$1,500
194
POWELL, ROBERT TYLER
$1,500
195
ROBERTSON, DAVID
$1,500
196
SHOUSHANIAN, MARTIN A.
$1,500
197
SIDDIQUI, ARSHI
$1,500
198
SMITH, WALLACE
$1,500
199
SPIELER, NORMAN
$1,500
200
SUNTAG, AARON
$1,500
201
WILLIAMS, PETER
$1,500
202
GILBERT, DAN
$1,400
203
MITCHELL, KELLY
$1,400
204
WALSH, BRENDAN
$1,300
205
BLINDER, MADELINE
$1,250
206
KELLY, JOHN
$1,200
207
OKEEFE, PETER
$1,200
208
RYAN, JIMMY
$1,200
209
IJAZ, MUJEEB
$1,150
210
WHITEHORN, SAM E.
$1,050
211
ADAMS, C. DAN
$1,000
212
AMBROSE, STEVEN
$1,000
213
ANDERSON, KAREN
$1,000
214
ANDERSON, PEGGY
$1,000
215
ANTISHIN, DIANE
$1,000
216
ANTONE, N. PETER
$1,000
217
ASHFORD, JOHN
$1,000
218
BAKER, CALEB
$1,000
219
BARNWELL, SAM
$1,000
220
BASMAJIAN, ROGER
$1,000
221
BEHM, MICHAEL J.
$1,000
222
BERGEN, DON
$1,000
223
BIEBER, RONALD J.
$1,000
224
BIGGS, RAYMOND A.
$1,000
225
BOZZELLA, JOHN T.
$1,000
226
BREAUX, JOHN
$1,000
227
BRENEMAN, JEFFREY
$1,000
228
BREWER, MARK C.
$1,000
229
BROGAN, MICHAEL J.
$1,000
230
BROITMAN, ELANA
$1,000
231
BRUZZANO, MARCO
$1,000
232
BURNS, RICHARD
$1,000
233
BUSCHER, JOHN
$1,000
234
CADE, GREGORY
$1,000
235
CAPUANO, MICHAEL
$1,000
236
CHAVEZ, JOANN
$1,000
237
COLLINS, BARRY
$1,000
238
COLLINS, JOHN
$1,000
239
CONNORS, NORA
$1,000
240
COOK, DAVID A.
$1,000
241
COOPER, GEORGE
$1,000
242
DASCHLE, NATHAN
$1,000
243
DAUST, ROXANNE
$1,000
244
DEHGHAN, BEHJAT
$1,000
245
DELEVORYAS, NANCY
$1,000
246
DEMERS, RAYMOND Y.
$1,000
247
DININO, PAUL
$1,000
248
DROSTE, EDWARD
$1,000
249
DUCATO, MICHAEL
$1,000
250
ENOCH, QUINCY
$1,000
251
ESSERMAN, SUSAN
$1,000
252
FARRELL, M. BRENNAN
$1,000
253
FERRIBY, ROBIN
$1,000
254
FICK, ERIC
$1,000
255
FINKEL, ROBERT J.
$1,000
256
FINN, JAMES
$1,000
257
FRIEDBERG, RICHARD M.
$1,000
258
FROELICH, CRAIG
$1,000
259
GAGNON, JOHN
$1,000
260
GEISSINGER, ANNE
$1,000
261
GERRISH, CAMPBELL
$1,000
262
GIBBS, THOMAS
$1,000
263
GOODMAN, WILLIAM
$1,000
264
GREENBERG, RONALD
$1,000
265
GREENE, MARGARET E.
$1,000
266
GUPTA, ASHOK K.
$1,000
267
HAIDLE, ANDREA T.
$1,000
268
HALLAHAN, KATE
$1,000
269
HEALD, RAY
$1,000
270
HEYDON, PETER N.
$1,000
271
HILL, JOEL
$1,000
272
HODGES, MICHAEL
$1,000
273
HOLMES, JAMES M.
$1,000
274
HOON, PHILIP
$1,000
275
HORAN, TERENCE
$1,000
276
HOROWITZ, BARBARA
$1,000
277
HUSTON, BLAKE
$1,000
278
JAMIAN, GREGORY
$1,000
279
JENSEN, JESSICA
$1,000
280
JINGOZIAN, PAUL
$1,000
281
JOHNSON, ARTHUR C.
$1,000
282
JOHNSON, CHARLES
$1,000
283
JONES, JONATHON
$1,000
284
KAZEROUNIAN, JILA
$1,000
285
KEATING, PETER M.
$1,000
286
KESSLER, GARY
$1,000
287
KNISELY, EVAN
$1,000
288
KOH, GRACE
$1,000
289
KRETZSCHMAR, RICHARD
$1,000
290
KRIEG, MARTHA
$1,000
291
KUNZ, JAMES W.
$1,000
292
LAMPARTER, MARY
$1,000
293
LAMPARTER, RON
$1,000
294
LARSEN, DINAH
$1,000
295
LAUER, TREVOR P.
$1,000
296
LEE, DENISE M.
$1,000
297
LEE, PATRICK
$1,000
298
LINGLE, CHRISTOPHER
$1,000
299
LIPSEY, RACHEL
$1,000
300
LOVE, KIMBERLY
$1,000
301
LOVIN, BRANDON
$1,000
302
MAKI, BRETT A.
$1,000
303
MALARKEY, TIMOTHY
$1,000
304
MANLEY, RICHARD
$1,000
305
MANTZ, JONATHAN
$1,000
306
MAXFIELD, MELISSA
$1,000
307
MILLER, RACHEL
$1,000
308
MOHLER, MARGARET A.
$1,000
309
MONSIF, SHANNON
$1,000
310
MOSKWA, PATTI ANN
$1,000
311
MUKKAMALA, BOBBY
$1,000
312
MUSTIN, LINK
$1,000
313
NETTERFIELD, KIM
$1,000
314
NEWHARD, ELEANOR
$1,000
315
NYHOLM, ALLISON
$1,000
316
OGDEN, JUDITH
$1,000
317
OLSON, ERIK
$1,000
318
PAGANO, ED
$1,000
319
PARETSKY, SARA
$1,000
320
PAUL, MATTHEW T.
$1,000
321
PERLMUTTER, NATHAN
$1,000
322
PERRY, EDMUND
$1,000
323
PLUNKETT, MICHAEL
$1,000
324
PLYBON, ROBERT
$1,000
325
POERSCH, JENNIFER
$1,000
326
PRATT, EVAN
$1,000
327
QUINN, THOMAS H.
$1,000
328
RAFFAELLI, JOHN D.
$1,000
329
ROGERS, JOHN W. JR.
$1,000
330
ROLLING, MARK
$1,000
331
ROSOWSKI, ROBERT B.
$1,000
332
RUEDIGER, STEPHEN
$1,000
333
RUUD, DAVID S.
$1,000
334
RYAN, JAMES
$1,000
335
SARKESIAN, PETER
$1,000
336
SCHWIND, JEROME E.
$1,000
337
SHEWCRAFT, SCOTT
$1,000
338
SHROYER, JULIE E.
$1,000
339
SILVERMAN, STEPHANIE
$1,000
340
SIMON, NEAL S.
$1,000
341
SIMPSON, MICHAEL
$1,000
342
SINGH, JASPREET
$1,000
343
SIRACUSE, HELEN
$1,000
344
SOSNICK, SUSAN M.
$1,000
345
STUPAK, BART T.
$1,000
346
SWARTZ, STEPHEN
$1,000
347
TATE, DANIEL JR
$1,000
348
THOMAS, DAVID
$1,000
349
THOMAS, SAMUEL BUZZ III
$1,000
350
TODD, WILL
$1,000
351
VAN DUSEN, GEORGE
$1,000
352
VAN HEUVELEN, ROBERT
$1,000
353
VEALENCIS, JOE
$1,000
354
WALKER, BRAD
$1,000
355
WALSH, KEVIN
$1,000
356
WARE, MARK
$1,000
357
WARNER, RICHARD
$1,000
358
WATSON, JOHN S.
$1,000
359
WEBSTER, PETER
$1,000
360
WERNER, MICHAEL
$1,000
361
WEXLER, DAVID
$1,000
362
WILLIAMS, MICHAEL
$1,000
363
WINSLOW, SALLY
$1,000
364
WOODY, MICHAEL
$1,000
365
ZANGENEH, KARIM
$1,000
366
MATLOCK, MARK
$970
367
KATZ, JORDON
$950
368
MULLIN, PETER W.
$900
369
SANFORD, JOHN
$800
370
SCHWARTZ, ARI
$800
371
ADRABI, JONATHAN
$750
372
O'BRIEN, LAWRENCE F. III
$750
373
ALIX, JAY
$700
374
CRANWELL, WILLIAM C.
$700
375
BLIGHT, CATHY
$600
376
GALEANA, CARL
$600
377
MORGANROTH, MAYER W.
$600
378
MOSS, SIDNEY
$600
379
TEJRAL, AMY
$600
380
WESLEY, CORNELIA
$600
381
BHUTA, JED
$550
382
PAYNTER, RANN
$533
383
AGGARWAL, RAGHAV
$500
384
ALAFCHI, MOHAMMAD
$500
385
ALMURAISI, NAGAT
$500
386
ANAYA, WILLIAM
$500
387
ARABIA, CHERIE
$500
388
ARONSON, LAUREN
$500
389
BARENS, KRISTI
$500
390
BECKHUSEN, ERIC
$500
391
BLANKLEY, JOHN
$500
392
BONO, RANDALL
$500
393
BRADLEY, KEVIN W.
$500
394
BRATHWAITE, PAUL A.
$500
395
BRIM, REMY
$500
396
BROWN, CYNTHIA
$500
397
BURTON, STEPHEN R.
$500
398
CALLE, JON
$500
399
CAMPBELL, THOMAS
$500
400
CATTON, JACK
$500
401
CHASE, NELSON
$500
402
COCKRELL, ERIC
$500
403
COHN, ALAN
$500
404
COOPERMAN, JOEL
$500
405
CORUM, KENTON R.
$500
406
DABANIAN, JUDITH C.
$500
407
DARAKJIAN, ARA
$500
408
DAVIS, CHRISTOPHER
$500
409
DAVIS, GILBERT R.
$500
410
DE BURLO, C. RUSSELL
$500
411
DENENFELD, PAUL J.
$500
412
DENHAM, LORI
$500
413
DEOL, SATVIR
$500
414
DONG, TOM
$500
415
DRISCOLL, JERRY
$500
416
DROBAC, MICHAEL
$500
417
DUDZIK, MICHAEL
$500
418
DUNN, BARBARA
$500
419
EICHLER, EDWIN H.
$500
420
ELLIOTT ANDAHAZY, MORGAN
$500
421
EMANUEL, ADAM
$500
422
ERB, JUDITH L.
$500
423
ERVIN, FRANK W. III
$500
424
ESQUITH, STEPHEN
$500
425
EUGENE, LOVASCO
$500
426
EVENSON, VERNON
$500
427
FARRIS, RYAN
$500
428
FEI, ROBERT
$500
429
FIELDS, ANDREW
$500
430
FISH, GRETCHEN
$500
431
FORRESTER, TERRY
$500
432
FOSTER, BRENDA
$500
433
FRANK, SARA B.
$500
434
GARDINER, JOHN
$500
435
GARGARO, EUGENE A. JR
$500
436
GARNER, ROBERT
$500
437
GAZDA, ELAINE H.
$500
438
GENTILLE, SALLY
$500
439
GUZIK, JOHN
$500
440
HALE, ROBERT
$500
441
HARDISON, ROBERT
$500
442
HARDY, LAURA
$500
443
HARTWICK, SHANNEN
$500
444
HAYNES, SARAH
$500
445
HEITNER, KENNETH
$500
446
HETTINGER, LUKE
$500
447
HICKS, MATTHEW
$500
448
HIEBER, ERIC
$500
449
HOLMES, BOB
$500
450
HOLTZ, JUDITH A.
$500
451
HONNOLD, TERESA R.
$500
452
HOOSANG, CHRISTOPHER P.
$500
453
HUCK, DAVID E.
$500
454
HUMPHREY, LEE
$500
455
HURST, BRET
$500
456
ISRAELYAN, SOUREN
$500
457
JACKSON, CARLOS
$500
458
JENSEN, CAROL
$500
459
JOHNSON, CAROLYN J.
$500
460
JOHNSON, JEFFREY
$500
461
JOHNSON, SHANE
$500
462
JUDD, TERAN
$500
463
KAMENS, MARY S.
$500
464
KATZ, ANN F.
$500
465
KELLEMS, CHRISTINE
$500
466
KELLY, KENNETH
$500
467
KEZELIAN, HARRY A. III
$500
468
KITCHENMASTER, JOYCE
$500
469
KLEIN, BENJAMIN
$500
470
KOCHERIL, PAUL
$500
471
KOPELMAN, JEFFREY
$500
472
KOTT, JONATHAN
$500
473
KULHANJIAN, PAUL
$500
474
LAGANGA, SCOTT
$500
475
LAMBERT, SANDRA
$500
476
LARSON, MYRA
$500
477
LETOURNEAU, DARIN
$500
478
LEWIN, ANDREW
$500
479
LIPAR, ANDREW G.
$500
480
LURIE, ALEXANDER D.
$500
481
MA, ANA
$500
482
MACFARLANE, JOHN T.
$500
483
MAGUIRE, PATRICK
$500
484
MAHONY, SHEILA
$500
485
MAMASSIAN, GREGORY
$500
486
MANOCHERIAN, BERNICE
$500
487
MARSHALL, TIMOTHY G.
$500
488
MARTIN, KENNETH B.
$500
489
MATTESON, NORMA
$500
490
MATTHEWS, JANE
$500
491
MCCLINTOCK, JANET M.
$500
492
MCKEAN, KATHERINE
$500
493
MCKEONE, JAMES
$500
494
MCKIE, KEVIN
$500
495
MCNAMARA, PATRICK
$500
496
MEADE, HEATHER
$500
497
MELMAN, MAARTHA
$500
498
MICHELOTTI, ROBERT J.
$500
499
MILLER, DEBORAH L.
$500
500
MONTGOMERY, JANET
$500
501
MOON, LAWRENCE E.
$500
502
MOORE, JUDITH
$500
503
MOORE, MAURICE
$500
504
MUGAR, CAROLYN
$500
505
MULLEN, MIKE
$500
506
NARAYAN, SESHADRI
$500
507
NICKEL, CLAUDIA
$500
508
NORCROSS, JULIE
$500
509
NUNLEY, NICHOLAS
$500
510
ONEILL, MARTIN
$500
511
OROSZ, JOEL J.
$500
512
OSENBERG, THOMAS
$500
513
OSTRO, ZACHARY
$500
514
OUDSEMA, ROBERT N. JR
$500
515
PALMER, TIM
$500
516
PANDRANGI, DAMAYANTHI V.
$500
517
PANZA, LUCIA
$500
518
PERRY, DAVID
$500
519
PFEUFFER, SHARON
$500
520
PHILLIPS, MATT
$500
521
PHILLIPS, MATTHEW
$500
522
PITTLEMAN, ETHAN
$500
523
PITTS, LAWRENCE
$500
524
QUEISSER, BRAD
$500
525
RABEN, MARGARET MARY
$500
526
RANKIN, VIRGINIA
$500
527
RAYMOND, LISA
$500
528
REILLY, EDWARD
$500
529
REISS, BILLIE
$500
530
RIGGS, JIMMY W.
$500
531
RILEY, MICHAEL V.
$500
532
ROSEN, ERIC
$500
533
ROSENBERG, VALERIE
$500
534
ROSENKRANDS, MARGARET R.
$500
535
ROSENSTOCK, JASON
$500
536
ROTHSCHILD, GREGG
$500
537
RUBENFIRE, MELVYN
$500
538
SABOURIN, DONALD
$500
539
SALO, AMY
$500
540
SAMET, CYRUS
$500
541
SANCHEZ-MURPHY, ANTONIA
$500
542
SCHULZ, JEAN F.
$500
543
SCRIBNER, CHRIS
$500
544
SEARS, KINGSLEY G. JR.
$500
545
SEDILLO, MARY A.
$500
546
SENECO, FRANCIS
$500
547
SENECO, FRANK
$500
548
SIEROTY, ALAN
$500
549
SMITH-OLSON, DEBORAH
$500
550
SRIVASTAVA, AJAY
$500
551
STRASBERG, TREGER S.
$500
552
SUES, ROB
$500
553
TANENBAUM, JUDITH
$500
554
THELEN, MARK
$500
555
THOMPSON, BRADLEY
$500
556
THORNELL, PAUL
$500
557
TOBIN, JUDY
$500
558
TOLL, SHELDON
$500
559
TORSHIAI, GLENN
$500
560
TOTTY, COLLEEN
$500
561
TURNER, FRED
$500
562
VECCHIONE, PAUL
$500
563
VETTE, SUSAN
$500
564
WALDMAN, BARRY P.
$500
565
WALKER-MILLER, CARLA
$500
566
WALTER, SARAH
$500
567
WALTZ, MALINDA H.
$500
568
WEISS, JEFFREY
$500
569
WILCOX, JUDY
$500
570
WOHLLEB, MARY
$500
571
YURK, PAM
$500
572
ZAMANI, BATOOL
$500
Cosponsors & Their Campaign Finance
This bill has 7 cosponsors. Below are their top campaign contributors.
Sen. Lankford, James [R-OK]
ID: L000575
Top Contributors
22
1
MUSCOGEE CREEK NATION
OrganizationOKMULGEE, OK
$1,000
Oct 29, 2024
2
HUNTON ANDREWS KURTH LLP
OrganizationRICHMOND, VA
$1,000
Aug 4, 2023
3
SAMPLES, RYAN
SAMPLES GROUP • MANAGEMENT
IndividualOKLAHOMA CITY, OK
$6,600
Aug 30, 2023
4
KAY, ALISON
KIDS CAPITAL • HEDGE FUND MANAGER
IndividualBEVERLY HILLS, CA
$6,600
Jun 20, 2023
5
KANADY, CHRISTIAN
ECHO INVESTMENT CAPITAL, LLC • CEO
IndividualNICHOLS HILLS, OK
$6,600
Jun 10, 2024
6
MANDELBLATT, DANIELLE
RETIRED
IndividualASPEN, CO
$6,600
Jul 31, 2024
7
MANDELBLATT, ERIC
SOROBAN CAPITAL PARTNERS LP • MANAGING PARTNER
IndividualASPEN, CO
$6,600
Jul 31, 2024
8
ROWAN, CAROLYN
CAROLYN ROWAN COLLECTION • OWNER
IndividualNEW YORK, NY
$6,600
Sep 30, 2024
9
ROWAN, MARC J.
APOLLO GLOBAL MANAGEMENT • CEO
IndividualNEW YORK, NY
$6,600
Sep 30, 2024
10
ARMSTRONG, SINCLAIR WALKER JR.
ARMSTRONG BANK • CHAIRMAN OF THE BOARD
IndividualVIAN, OK
$6,600
Aug 30, 2023
Sen. Ernst, Joni [R-IA]
ID: E000295
Top Contributors
23
1
SAC & FOX TRIBE OF MISSISSIPPI IN IOWA
OrganizationTAMA, IA
$5,000
Aug 29, 2023
2
SAC & FOX TRIBE OF MISSISSIPPI IN IOWA
OrganizationTAMA, IA
$1,700
Sep 28, 2023
3
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$1,000
May 21, 2024
4
ABEL, ANDREA MS.
HOMEMAKER • HOMEMAKER
IndividualDES MOINES, IA
$50,000
Feb 7, 2023
5
MCINERNEY, THOMAS E. MR.
BLUFF POINT ASSOC. CORPORATION • VENTURE INVESTOR
IndividualWESTPORT, CT
$50,000
Feb 22, 2023
6
NICOLLS, BOB MR.
MONARCH • REAL ESTATE
IndividualFRANKTOWN, CO
$25,000
Mar 17, 2023
7
GRAY, C. BOYDEN
SELF-EMPLOYED • ATTORNEY
IndividualWASHINGTON, DC
$25,000
Mar 29, 2023
8
CATSIMATIDIS, JOHN A. MR.
UNITED REFINING COMPANY • CHARIMAN & CEO
IndividualNEW YORK, NY
$25,000
May 16, 2023
9
KOTICK, ROBERT MR.
ACTIVISION BLIZZARD • CEO
IndividualSANTA MONICA, CA
$16,600
Dec 20, 2024
10
VINCZE, CHRISTOPHER
TRC COMPANIES INC. • CHAIRMAN AND CEO
IndividualTEQUESTA, FL
$15,800
Nov 6, 2023
Sen. Cotton, Tom [R-AR]
ID: C001095
Top Contributors
24
1
WINRED
PACARLINGTON, VA
$1,919
Mar 7, 2024
2
CLARK COUNTY REPUBLICAN COMMITTEE
OrganizationARKADELPHIA, AR
$600
Mar 4, 2024
3
YELL COUNTY REPUBLICAN COMMITTEE
OrganizationDARDANELLE, AR
$500
Jan 17, 2024
4
DARDANELLE CHAMBER OF COMMERCE
OrganizationDARDANELLE, AR
$400
Jan 26, 2024
5
RAMSEY, JASON
RAGNAR • MANAGER
IndividualBREVARD, NC
$11,600
Jul 11, 2023
6
KLINGENSTEIN, THOMAS D. MR.
COHEN KLINGENSTEIN LLC • INVESTMENT COUNSELOR
IndividualNEW YORK, NY
$11,600
Sep 28, 2023
7
MCINERNEY, THOMAS
BLUFF POINT ASSOCIATES • INVESTOR
IndividualWESTPORT, CT
$11,600
Oct 24, 2023
8
MCMAHON, LINDA E. MRS.
AMERICA FIRST POLICY INSTITUTE • SELF-EMPLOYED
IndividualGREENWICH, CT
$11,600
Oct 31, 2023
9
CHIAPPA, CARL
RETIRED • RETIRED
IndividualOLD CHATHAM, NY
$11,600
Nov 9, 2023
10
SCHWARZMAN, CHRISTINE
RETIRED • RETIRED
IndividualNEW YORK, NY
$11,600
Jan 11, 2024
Sen. Kaine, Tim [D-VA]
ID: K000384
Top Contributors
30
1
THE CHICKASAW NATION
OrganizationADA, OK
$2,300
Jun 18, 2024
2
THE CHICKASAW NATION
OrganizationADA, OK
$1,000
Jun 26, 2023
3
SAN MANUEL BAND OF MISSION INDIANS
OrganizationLOS ANGELES, CA
$1,000
Jun 18, 2024
4
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$1,000
Jun 25, 2024
5
THE CHICKASAW NATION
OrganizationADA, OK
$1,000
Jun 18, 2024
6
CHOCTAW NATION OF OKLAHOMA
OrganizationDURANT, OK
$1,000
Oct 15, 2024
7
CHEROKEE NATION
OrganizationTAHLEQUAH, OK
$1,000
Dec 29, 2023
8
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$600
Oct 25, 2023
9
STONEHALL FARM
OrganizationTHE PLAINS, VA
$500
Jun 30, 2024
10
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$400
Oct 25, 2023
Sen. King, Angus S., Jr. [I-ME]
ID: K000383
Top Contributors
24
1
2120 SEA ISLAND LLC
OrganizationRIVER FOREST, IL
$3,300
Oct 26, 2023
2
THE CHICKASAW NATION
OrganizationADA, OK
$3,300
May 22, 2024
3
THE CHICKASAW NATION
OrganizationADA, OK
$2,000
Mar 29, 2024
4
THE CHICKASAW NATION
OrganizationADA, OK
$1,300
May 22, 2024
5
SMITH, BRAD
MICROSOFT CORPORATION • ATTORNEY
IndividualBELLEVUE, WA
$6,600
Feb 13, 2024
6
SMITH, BRAD
IndividualBELLEVUE, WA
$6,600
Feb 20, 2024
7
DOWNEY, NANCY A.
IndividualNEW YORK, NY
$5,000
Sep 4, 2024
8
DOWNEY, NANCY A.
NOT EMPLOYED • RETIRED
IndividualNEW YORK, NY
$5,000
Aug 31, 2024
9
OTTEN, LESLIE B.
AMERICAN SKIING COMPANY • OWNER
IndividualBETHEL, ME
$5,000
Oct 4, 2024
10
BEKENSTEIN, ANITA
NOT EMPLOYED • RETIRED
IndividualWAYLAND, MA
$3,300
Oct 24, 2024
Sen. Scott, Rick [R-FL]
ID: S001217
Top Contributors
22
1
SEMINOLE TRIBE OF FLORIDA
OrganizationHOLLYWOOD, FL
$3,300
Aug 22, 2023
2
SEMINOLE TRIBE OF FLORIDA
OrganizationHOLLYWOOD, FL
$3,300
Aug 12, 2024
3
SCOTT, RICK SENATOR
US SENATE • US SENATOR
IndividualTAMPA, FL
$90,795
May 31, 2024
4
SCOTT, RICK SEN
US SENATE • US SENATOR
IndividualWASHINGTON, DC
$77,714
May 31, 2023
5
SCOTT, RICK SENATOR
US SENATE • US SENATOR
IndividualTAMPA, FL
$69,607
Apr 30, 2024
6
SCOTT, RICK SENATOR
US SENATE • US SENATOR
IndividualTAMPA, FL
$68,538
Aug 31, 2023
7
SCOTT, RICK SENATOR
US SENATE • US SENATOR
IndividualTAMPA, FL
$53,187
Sep 30, 2023
8
SCOTT, RICK SEN
US SENATE • US SENATOR
IndividualWASHINGTON, DC
$49,992
Jun 30, 2023
9
SCOTT, RICK SENATOR
US SENATE • US SENATOR
IndividualTAMPA, FL
$39,695
Jun 30, 2024
10
SCOTT, RICK
US SENATE • US SENATOR
IndividualWASHINGTON, DC
$34,494
Jan 31, 2023
Sen. Slotkin, Elissa [D-MI]
ID: S001208
Top Contributors
35
1
MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS
OrganizationSHELBYVILLE, MI
$3,300
Oct 31, 2024
2
SAULT STE. MARIE TRIBE OF CHIPPEWA INDIANS
OrganizationSAULT SAINTE MARIE, MI
$3,300
Oct 31, 2024
3
CHEROKEE NATION
OrganizationTAHLEQUAH, OK
$3,300
Dec 31, 2023
4
THE CHICKASAW NATION
OrganizationADA, OK
$3,300
Mar 21, 2024
5
SHAKOPEE MDEWAKANTON SIOUX COMMUNITY
OrganizationPRIOR LAKE, MN
$3,300
Jun 30, 2024
6
THE CHICKASAW NATION
OrganizationADA, OK
$3,300
Jun 10, 2024
7
MASHANTUCKET PEQUOT TRIBAL NATION
OrganizationMASHANTUCKET, CT
$3,300
Sep 29, 2023
8
MATCH-E-BE-NASH-SHE-WISH BAND OF POTTAWATOMI INDIANS
OrganizationSHELBYVILLE, MI
$3,300
Sep 29, 2023
9
SEMINOLE TRIBE OF FLORIDA
OrganizationHOLLYWOOD, FL
$3,300
Sep 29, 2023
10
HABEMATOLEL POMO OF UPPER LAKE
OrganizationUPPER LAKE, CA
$3,300
Sep 27, 2024
Donor Network - Sen. Peters, Gary C. [D-MI]
PACs
Organizations
Individuals
Politicians
Hub layout: Politicians in center, donors arranged by type in rings around them.
Loading...
Showing 52 nodes and 74 connections
Total contributions: $74
Top Donors - Sen. Peters, Gary C. [D-MI]
Showing top 18 donors by contribution amount
12 Orgs6 Individuals
Industry Impact
Which industries are materially affected by specific provisions in this bill. 1 helped.
- +Biotech & Researchconfidence 0.80
Biotech firms involved in active pharmaceutical ingredient production and advanced manufacturing (as defined in Section 6) would benefit from the bill's focus on mapping supply chains, identifying domestic manufacturing capabilities, and promoting advanced manufacturing technologies for essential medicines (Sections 3(b)(4), 4(a)(2), 6).
Who funds the sponsor on these industries
For each industry this bill affects, here's what the sponsor (Sen. Peters, Gary C. [D-MI])received from donors associated with that industry during the 2022–present cycles. Donations are not proof of intent — they are a record of who funds the people writing the law.
Industries this bill HELPS
- Biotech & Research$3,590from 26 contributions
- HARDY, ALEXANDER$3,300
- DOBOS, ANDREW$240
- VANDERLAAN, MARTIN$50
Project 2025 Policy Matches
This bill shows semantic similarity to the following sections of the Project 2025 policy document.AI-enhanced analysis provides detailed alignment ratings.
Department of Health and Human Services
Strong
Vector: 65%Pages: 488-490AI Enhanced
AI Analysis:
"The MAPS Act's focus on identifying essential medicines, assessing supply chain risks, and promoting domestic manufacturing aligns closely with Project 2025's objectives to reduce drug shortages, strengthen generic drug manufacturing, and enhance FDA/HHS oversight of pharmaceutical supply chains."
Key themes:drug supply chain resiliencegeneric drug manufacturingFDA/HHS coordinationreducing foreign relianceaddressing drug shortages
— 456 — Mandate for Leadership: The Conservative Promise abortion providers and whether better prenatal physical, mental, and social care improves infant outcomes and decreases abortion rates, especially among those who are most vulnerable. The Ensuring Accurate and Complete Abortion Data Reporting Act of 20239 would amend title XIX of the Social Security Act and Public Health Service Act to improve the CDC’s abortion reporting mechanisms by requiring states, as a condition of federal Medicaid payments for family planning services, to report streamlined variables in a timely manner. The CDC should immediately end its collection of data on gender identity, which legitimizes the unscientific notion that men can become women (and vice versa) and encourages the phenomenon of ever-multiplying subjective identities. FOOD AND DRUG ADMINISTRATION (FDA) The FDA’s mission includes ensuring the safety and efficacy of drugs, biological products, and medical devices. Federal Laws That Shield Big Pharma from Competition. Because generics generally cost far less than brand-name drugs, consumers begin to save money as soon as a generic product comes on the market. The vast majority are very afford- able with 93 percent of generic products costing $20 or less. Savings would be even higher under proposals that prevent brand-name man- ufacturers from slowing down or impeding the entrance of generic products into the marketplace. Specifically, the FDA should prohibit pharmaceutical companies from purposely sitting on their legally available right to be the first to sell generic versions of their drugs. Additionally, Congress should create legal remedies for generic companies to obtain samples of brand-name products for their generic development efforts and should prohibit meritless “citizen petitions” submitted by manufacturers to delay approval of a generic competitor.10 Approval Process for Laboratory-Developed or Modified Medical Tests. Learning from the failed early COVID-19 testing experience, Congress and the FDA should focus on reforming laws and regulations governing medical tests, especially with respect to laboratory-developed tests. Commercial tests are developed with the intention of being widely marketed, distributed, and used, while laboratory-developed tests are created with the intention of being used solely within one laboratory. A test developed by a lab in accordance with the protocols developed by another lab (non-commercial sharing) currently constitutes a “new” laboratory-developed test because the lab in which it will be used is different from the initial developing lab. To encourage interlab- oratory collaboration and discourage duplicative test creation (and associated regulatory and logistical burdens), the FDA should introduce mechanisms through which laboratory-developed tests can easily be shared with other laboratories with- out the current regulatory burdens.11 — 457 — Department of Health and Human Services The “laboratory-developed tests” category currently encompasses a range of possible tests, many of which would be characterized more appropriately as “lab- oratory-modified tests” because they are not truly novel tests but rather modified versions of existing tests. To avoid stifling innovation and access to medical care, the applicable statutes and regulations should be revised to facilitate greater access to such modified tests.12 Finally, the FDA has long held that it has regulatory authority over such tests, while others have argued that they should be considered clinical services regulated by the Centers for Medicare and Medicaid Services (CMS). The FDA currently has regulatory authority over in vitro diagnostics, and under the Clinical Lab- oratory Improvement Amendments (CLIA),13 the CMS ensures that labs meet analytical validity standards for test methods. Congress, the FDA, and the CMS need to clarify and disentangle overlapping authorities over tests to eliminate regulatory confusion.14 Drug Shortages. The very thin profit margins and the regulatory burdens associated with generic drug manufacturing discourage inventory and capacity investments by manufacturers and contribute to drug shortages. HHS and the FDA should encourage more dependable generic drug manufacturing. The FDA should expand its current pass/fail approach to drug facility inspec- tions into a graded system that recognizes manufacturers that exceed minimum standards by investing in improving production reliability. The FDA should also add facility codes to drug packaging and construct a searchable database that cross-references product codes and facility codes. That would enable wholesalers and pharmacy benefit managers to identify and preference drugs manufactured at more reliable facilities, thus encouraging generic drug manufacturers to compete on reliability as well as on price. For its part, HHS should exempt multi-source generic drugs from requirements to pay rebates to Medicaid and other federally funded health programs, as those provisions penalize new investments in expanding manufacturing capacity when supply is unable to meet demand.15 Additionally, FDA and NIH should promote efficacy trials of new applications for generic drugs, which might include NIH fund- ing such trials or conducting its own. Abortion Pills. Abortion pills pose the single greatest threat to unborn chil- dren in a post-Roe world. The rate of chemical abortion in the U.S. has increased by more than 150 percent in the past decade; more than half of annual abortions in the U.S. are chemical rather than surgical. The abortion pill regimen is typically a two-part process. The first pill, mifepris- tone, causes the death of the unborn child by cutting off the hormone progesterone, which is required to sustain a pregnancy. The second pill, misoprostol, causes con- tractions to induce a delivery of the dead child and uterine contents, usually into a toilet at home. The abortion-pill regimen is currently approved for up to 70 days
Department of Health and Human Services
Strong
Vector: 61%Pages: 533-535AI Enhanced
AI Analysis:
"The MAPS Act’s focus on strengthening essential medicine supply chains, assessing risks, and boosting domestic manufacturing aligns with Project 2025’s HHS objectives of reducing foreign dependence and enhancing national security resilience in healthcare."
Key themes:pharmaceutical supply chain resiliencedomestic manufacturing promotionrisk assessmentnational securitypublic-private partnerships
— 500 — Mandate for Leadership: The Conservative Promise 32. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 33. Brian Blase, “Managed Care in Medicaid: Need for Oversight, Accountability, and Reform,” Paragon Health Institute Policy Brief, October 13, 2022, https://paragoninstitute.org/wp-content/uploads/2022/10/20221012- Managed-Care-in-Medicaid-Need-for-Oversight-Accountability-and-Reform-FOR-DISTRIBUTION-V2.pdf (accessed February 13, 2023). 34. Owcharenko Schaefer, “Medicaid at 55: Understanding the Design, Trends, and Reforms Needed to Improve the Health Care Safety Net.” 35. 42 U.S. Code § 1315, https://www.law.cornell.edu/uscode/text/42/1315 (accessed March 17, 2023). 36. Chad D. Savage and Lee S. Gross, “Direct Primary Care: Update and Road Map for Patient-Centered Reforms,” Heritage Foundation Backgrounder No. 3635, June 28, 2021, https://www.heritage.org/sites/default/ files/2021-06/BG3635.pdf. 37. H.R. 133, Consolidated Appropriations Act, 2021, Public Law No. 116-260, 116th Congress, December 27, 2020, Division BB, Title I, https://www.congress.gov/116/plaws/publ260/PLAW-116publ260.pdf (accessed March 17, 2023). 38. Doug Badger, “On Surprise Medical Bills, Congress Should Side with Consumers, Not Special Interests,” Heritage Foundation Commentary, January 31, 2020, https://www.heritage.org/health-care-reform/ commentary/surprise-medical-bills-congress-should-side-consumers-not-special. 39. Edmund F. Haislmaier and Abigail Slagle, “Premiums, Choices, Deductibles, Care Access, and Government Dependence Under the Affordable Care Act: 2021 State-by-State Review,” Heritage Foundation Backgrounder No. 3668, November 2, 2021, https://www.heritage.org/sites/default/files/2021-11/BG3668.pdf. 40. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, “Transparency in Coverage,” Final Rule, Federal Register, Vol. 85, No. 219 (November 12, 2020), pp. 72158–72310, https://www.govinfo.gov/ content/pkg/FR-2020-11-12/pdf/2020-24591.pdf (accessed March 17, 2023). 41. David N. Bernstein and Robert E. Moffit, “New Price Transparency Rule Will Help Transform America’s Health Care System,” Heritage Foundation Commentary, November 1, 2020, https://www.heritage.org/health-care- reform/commentary/new-price-transparency-rule-will-help-transform-americas-health-care. 42. Sluzala and Haislmaier, “Lessons from COVID-19: How Policymakers Should Reform the Regulation of Clinical Testing.” 43. Ibid. 44. Most recently enacted in H.R. 2471, Consolidated Appropriations Act, 2022, Public Law No. 117-103, 117th Congress, March 15, 2022, Division H, Title V, §§ 506–507, https://www.congress.gov/117/plaws/publ103/ PLAW-117publ103.pdf (accessed March 17, 2023). 45. President Joseph R. Biden Jr., Executive Order 14079, “Securing Access to Reproductive and Other Healthcare Services,” August 3, 2022, in Federal Register, Vol. 87, No. 154 (August 11, 2022), pp. 49505–49507, https:// www.govinfo.gov/content/pkg/FR-2022-08-11/pdf/2022-17420.pdf (accessed March 16, 2023). 46. Planned Parenthood, 2020–2021 Annual Report, p. 27, https://www.plannedparenthood.org/uploads/ filer_public/40/8f/408fc2ad-c8c2-48da-ad87-be5cc257d370/211214-ppfa-annualreport-20-21-c3-digital.pdf (accessed March 22, 2023). 47. Ibid., pp. 30 and 31. Total revenue of $1,714.4 million (p. 30) minus $1,580.7 million in total expenses (p. 31) yields $133,7 million. 48. Ibid., p. 28. 49. Ibid., p. 30. 50. H.R. 372, Protecting Life and Taxpayers Act of 2023, 118th Congress, introduced January 17, 2023, https://www. congress.gov/118/bills/hr372/BILLS-118hr372ih.pdf (accessed March 17, 2023). 51. 42 U.S. Code § 18023, https://www.law.cornell.edu/uscode/text/42/18023 (accessed March 17, 2023). 52. H.R. 3128, Consolidated Omnibus Budget Reconciliation Act of 1985, Public Law No. 99-272, 99th Congress, April 7, 1986, Title IX, Subtitle A, Part 1, Subpart B, § 9121, https://www.congress.gov/99/statute/STATUTE-100/ STATUTE-100-Pg82.pdf (accessed March 17, 2023). 53. H.R. 8070, Rehabilitation Act of 1973, Public Law No. 93-112, 93rd Congress, September 26, 1973, https://www. congress.gov/93/statute/STATUTE-87/STATUTE-87-Pg355.pdf (accessed March 17, 2023). — 501 — Department of Health and Human Services 54. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, Office of Civil Rights, and Office of the Secretary, “Special Responsibilities of Medicare Hospitals in Emergency Cases and Discrimination on the Basis of Disability in Critical Health and Human Service Programs or Activities,” draft of Proposed Rule, January 14, 2021, https://www.hhs.gov/sites/default/files/infants-nprm.pdf (accessed March 17, 2023). 55. H.R. 26, Born-Alive Abortion Survivors Protection Act, 118th Congress, introduced January 9, 2023, https:// www.congress.gov/118/bills/hr26/BILLS-118hr26pcs.pdf (accessed March 17, 2023). 56. H.R. 7, No Taxpayer Funding for Abortion and Abortion Insurance Full Disclosure Act of 2023, 118th Congress, introduced January 9, 2023, https://www.congress.gov/118/bills/hr7/BILLS-118hr7ih.pdf (accessed March 17, 2023). 57. S. 401, Conscience Protection Act of 2021, 117th Congress, introduced February 24, 2021, https://www.congress. gov/117/bills/s401/BILLS-117s401is.pdf (accessed March 17, 2023). 58. U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, and Office of the Secretary, “Nondiscrimination in Health Programs and Activities,” Notice of Proposed Rulemaking; Notice of Tribal Consultation, Federal Register, Vol. 87, No. 149 (August 4, 2022), pp. 47824–47920, https://www.govinfo. gov/content/pkg/FR-2022-08-04/pdf/2022-16217.pdf (accessed March 17, 2023). 59. Ibid., p. 47916. 60. The regulation was not finalized before the end of the Administration. U.S. Department of Agriculture, Food and Nutrition Services, “Revision of Categorical Eligibility in the Supplemental Nutrition Assistance Program (SNAP),” Proposed Rule, Federal Register, Vol. 84, No. 142 (July 24, 2019), pp. 35570–55581, https:// www.federalregister.gov/documents/2019/07/24/2019-15670/revision-of-categorical-eligibility-in-the- supplemental-nutrition-assistance-program-snap (accessed March 17, 2023). 61. 45 Code of Federal Regulations § 75.300(c) and (d), https://www.ecfr.gov/current/title-45/subtitle-A/ subchapter-A/part-75/subpart-D/subject-group-ECFR911e5e1a30bfbcb/section-75.300 (accessed March 17, 2023). 62. H.R. 1750, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https:// www.congress.gov/117/bills/hr1750/BILLS-117hr1750ih.pdf (accessed March 17, 2023), and S. 656, Child Welfare Provider Inclusion Act of 2021, 117th Congress, introduced March 10, 2021, https://www.congress.gov/117/bills/ s656/BILLS-117s656is.pdf (accessed March 17, 2023). 63. S. 3949, Trafficking Victims Protection Reauthorization Act of 2022, Public Law No. 117-348, 117th Congress, January 25, 2023, https://www.congress.gov/117/plaws/publ348/PLAW-117publ348.pdf (accessed March 17, 2023). 64. Kelsey Y. Santamaria, “Child Migrants at the Border: The Flores Settlement Agreement and Other Legal Developments,” Congressional Research Service In Focus No. IF11799, April 1, 2021, https://crsreports.congress. gov/product/pdf/IF/IF11799 (accessed March 17, 2023). 65. Report, Building a Happy Home: Marriage Education as a Tool to Strengthen Families, Social Capital Project Report No. 1-22, March 2022, p. 17, https://www.jec.senate.gov/public/_cache/files/3d102525-6f0d-48ed- 92f4-d71edd468ad6/building-a-happy-home.pdf (accessed March 17, 2023). The cover of the report reflects that the Social Capital Project is “[a] project of the Joint Economic Committee – Republicans.” 66. See, for example, Alan J. Hawkins, “Are Federally Supported Relationship Education Programs for Lower-Income Individuals and Couples Working? A Review of Evaluation Research,” American Enterprise Institute, September 2019, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 67. H.R. 8404, Respect for Marriage Act, Public Law No. 117-228, 117th Congress, December 13, 2022, https://www. congress.gov/117/plaws/publ228/PLAW-117publ228.pdf (accessed March 17, 2023). 68. Madison Marino, “Over 1,000 Safety Violations Mar Head Start. Children Deserve Better,” Heritage Foundation Commentary, November 10, 2022, https://www.heritage.org/education/commentary/over-1000-safety- violations-mar-head-start-children-deserve-better. 69. American Hospital Association v. Becerra, 596 U.S. ___ (2022), https://www.supremecourt.gov/ opinions/21pdf/20-1114_09m1.pdf (accessed March 17, 2023). 70. U.S. Department of the Treasury, Internal Revenue Service; U.S. Department of Labor, Employee Benefits Security Administration; and U.S. Department of Health and Human Services, Centers for Medicare and Medicaid Services, “Coverage of Certain Preventive Services Under the Affordable Care Act,” Notice of Proposed Rulemaking, Federal Register, Vol. 88, No. 22 (February 2, 2023), pp. 7236–7281, https://www. govinfo.gov/content/pkg/FR-2023-02-02/pdf/2023-01981.pdf (accessed March 17, 2023).
Trade
Moderate
Vector: 62%Pages: 840-842AI Enhanced
AI Analysis:
"The MAPS Act focuses on strengthening domestic pharmaceutical supply chains through risk assessment and mapping, which partially aligns with Project 2025's emphasis on supply chain resilience and reducing vulnerabilities. However, it diverges from Project 2025's preference for free trade solutions like mutual recognition and deregulation, instead favoring government-led coordination and domestic production incentives."
Key themes:supply chain resilienceessential medicinesnational securitydomestic manufacturingrisk assessment
— 808 — Mandate for Leadership: The Conservative Promise failure point crashed the whole system. It should not be that way, and the next President can change it. Part of the problem is that the supply chain analogy itself causes sloppy thinking. In a chain, a link is connected only to the link ahead of it and the link behind it and not to any other links. Real-world supply chains are more like networks in which each point connects directly to countless others and is rarely more than six degrees of separation from nearly anywhere on Earth. Because market failures happen all the time, it is important to have as many connections as possible. Americans need access to more ways to adapt and reroute around failure points, especially for essential products like baby formula. Trade protectionism makes us more vulnerable, but free trade makes our fam- ilies and communities more resilient. Loosening restrictions similar to the ones that stunt the baby formula market would make it easier to navigate future crises while preventing the progressive and rent-seeking power grabs that come with every crisis, whether it is as isolated as a baby formula shortage or as expansive as a pandemic. Mutual Recognition. A simple way to reduce friction in supply networks is mutual recognition of other industrialized countries’ regulatory standards. This can be done either in a larger trade agreement or independently. For baby for- mula, this would mean allowing in brands that meet European Union standards even if they do not meet Food and Drug Administration (FDA) labeling require- ments. Infants’ nutritional needs do not change across borders. If a formula is deemed healthy for European babies, then it is also healthy for American babies. The reverse is equally true. Mutual recognition could help to open new markets for American producers in countless industries and give American consumers access to countless new prod- ucts on more competitive terms. For example, U.S. regulations require washing machine power cords to be at least six feet long, while the U.K. requires them to be at least two meters.69 The difference (about six inches) affects neither safety nor performance, but it does keep American-made washing machines out of an import- ant foreign market. A mutual recognition policy would circumvent the problem. Given the recent interest in increased antitrust enforcement, conservatives should embrace policies like mutual recognition that have the double benefit of increasing market competition while decreasing government’s regulatory footprint. The U.S. should enact mutual recognition agreements for a wide variety goods with the United Kingdom, European Union, Japan, South Korea, Australia, and other governments with high standards comparable to our own. This would have especially large benefits for pharmaceuticals, because America’s FDA drug approval process is both slower and more expensive than those of other countries with- out being any safer. Americans would gain access to more and lower-cost medical — 809 — Trade treatments, and American pharmaceutical companies could defray development costs and innovate faster by gaining access to more markets, all while cutting prices. The Jones Act. The Jones Act (Merchant Marine Act of 1920)70 requires that ships traveling between U.S. ports must be U.S.-built, U.S.-owned, and U.S.-crewed. In practice, this is an “America last” policy that has decimated the American mari- time industry.71 Because of Jones Act regulations, American-built ships cost three to four times more to build than foreign-built ships cost. As a result, the entire Jones Act fleet is down to just 92 ships, many of which are old and obsolete. In fact, Jones Act–compliant shipping is so expensive that it is often cheaper for East Coast ports to import oil from Vladimir Putin’s Russia than it is to send it up the coast from Houston or New Orleans. The national security (to say nothing of energy security) implications of reliance on Russia for oil and gas are obvious. The Jones Act’s original national security justifications are just as dubious. The act’s goal was to guarantee a sizable fleet of American ships that could be pressed into war service if needed. Aircraft carriers and other post-1920 naval innovations have made this argument obsolete. An $800 billion defense budget has plenty of room to maintain a Navy to defend American security interests around the world. The U.S. Navy would likely prefer not to use Jones Act ships anyway, because they tend to be older and in poorer condition than its own ships or similar foreign-made but domestically owned commercial ships that could also be pressed into service. As with many other industries, U.S. shipbuilding could be the envy of the world if it could operate in a free market, but the maritime lobby prefers a quiet, cozy exis- tence on the dole even as it harms American consumers and national security. The next conservative Administration should unleash American potential by unilater- ally enacting Jones Act exemptions wherever allowed, as currently happens most years during hurricane season, and working with Congress to repeal the Jones Act. Trade and Inflation. The post-COVID inflation spike may be over long before the next Administration takes office, but keeping it under control should remain a high priority. Free traders should not oversell their case by saying that liberal- ization would solve inflation. Inflation is predominantly a monetary phenomenon, not a trade phenomenon, but tariff relief can help at the margin by immediately lowering prices on tariffed goods and slightly boosting long-term growth.72 While this would not affect the money supply, which is inflation’s key variable, even roll- ing back the tariffs enacted since 2017 would likely have a positive effect on the Consumer Price Index. The easiest way to curb inflation (or to create it) is for the Federal Reserve to work the monetary side of the equation, but the real output side has a similar effect on prices. Lifting trade barriers is one way to boost output. It also has the added benefit of requiring no additional spending. At the very least, this can make the Federal Reserve’s job easier as the spending excesses of Congress and President Biden continue unabated in the coming years.
Showing 3 of 5 policy matches
About These Correlations
Policy matches are calculated using a hybrid approach: initial candidates are found using semantic similarity between bill summaries and Project 2025 policy text, then an AI model (Llama 3.1 70B) provides detailed alignment ratings and analysis. Ratings range from 1 (minimal alignment) to 5 (very strong alignment). This analysis does not imply direct causation or intent.